Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP645898.RAU19eB2Q9FnYgJ7Y9P6g7F9zhf2hARQvcSHQKHpK3_AU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP645898.RAU19eB2Q9FnYgJ7Y9P6g7F9zhf2hARQvcSHQKHpK3_AU130_assertion type Assertion NP645898.RAU19eB2Q9FnYgJ7Y9P6g7F9zhf2hARQvcSHQKHpK3_AU130_head.
- NP645898.RAU19eB2Q9FnYgJ7Y9P6g7F9zhf2hARQvcSHQKHpK3_AU130_assertion description "[Subjects who developed lipoatrophy (n=10) had elevated fasting triglycerides [3.16 (sd 2.79) mmol/liter] and reduced insulin sensitivity as measured by frequently sampled iv glucose tolerance test [1.89 (sd 1.27)x10(-4) min(-1)/microU.ml] after 12 months, whereas those without lipoatrophy (n=21) did not show any metabolic complications [triglycerides 1.32 (sd 0.58) mmol/liter, P=0.01 vs. lipoatrophy; insulin sensitivity 3.52 (sd 1.91)x10(-4) min(-1)/microU.ml, P=0.01 vs. lipoatrophy].]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645898.RAU19eB2Q9FnYgJ7Y9P6g7F9zhf2hARQvcSHQKHpK3_AU130_provenance.
- NP645898.RAU19eB2Q9FnYgJ7Y9P6g7F9zhf2hARQvcSHQKHpK3_AU130_assertion evidence source_evidence_literature NP645898.RAU19eB2Q9FnYgJ7Y9P6g7F9zhf2hARQvcSHQKHpK3_AU130_provenance.
- NP645898.RAU19eB2Q9FnYgJ7Y9P6g7F9zhf2hARQvcSHQKHpK3_AU130_assertion SIO_000772 18089690 NP645898.RAU19eB2Q9FnYgJ7Y9P6g7F9zhf2hARQvcSHQKHpK3_AU130_provenance.
- NP645898.RAU19eB2Q9FnYgJ7Y9P6g7F9zhf2hARQvcSHQKHpK3_AU130_assertion wasDerivedFrom befree-2016 NP645898.RAU19eB2Q9FnYgJ7Y9P6g7F9zhf2hARQvcSHQKHpK3_AU130_provenance.
- NP645898.RAU19eB2Q9FnYgJ7Y9P6g7F9zhf2hARQvcSHQKHpK3_AU130_assertion wasGeneratedBy ECO_0000203 NP645898.RAU19eB2Q9FnYgJ7Y9P6g7F9zhf2hARQvcSHQKHpK3_AU130_provenance.